Biodel Inc (NASDAQ:BIOD)

p1a5244 (64.20) Submitted: 9/18/2011 11:19:12 PM : Start Price: $1.21 BIOD Score: -47.71

9/18/11 Options Predictor Rank #27. P/C Ratio 0.053 and Call Sizzle 3.477.

MotleyNYSE (< 20) Submitted: 3/18/2011 10:48:46 AM : Start Price: $2.19 BIOD Score: -68.12

This will outperform only if they receive FDA approval. Otherwise, this stock will die out like MannKind

Br0oklyn (< 20) Submitted: 1/20/2011 7:59:11 AM : Start Price: $2.27 BIOD Score: -69.76

It develops its product candidates by applying its formulation technologies to existing drugs.

modestus1 (< 20) Submitted: 1/13/2011 9:49:04 PM : Start Price: $2.55 BIOD Score: -73.25

insulin play

ExtremesTracker (27.37) Submitted: 12/7/2010 6:11:40 PM : Start Price: $1.78 BIOD Score: -64.72

picks source: zzlangerhans
as of 12/7/2010, these were the 5 most underperformed designated "top picks" by zz. these are the 5 picks (out 7 top picks):
alny,idra,rtix,biod,bdsi
No due diligence performed, these are hail marys that atleast a couple may possibly be insane multi baggers potentially
Very risky.

copydog1981 (< 20) Submitted: 10/8/2010 5:12:17 AM : Start Price: $4.52 BIOD Score: +97.02

They have some problems with the data of India.
So the best for the company that the FDA gives them a bit more time. Otherwist I don't see a approval

julianna8 (< 20) Submitted: 10/4/2010 10:51:37 AM : Start Price: $4.71 BIOD Score: -99.55

BUYBUYBUY!!!

BioInvestor217 (< 20) Submitted: 9/29/2010 12:08:15 AM : Start Price: $5.14 BIOD Score: -100.71

BIOD has quietly developed an improved mixed insulin product compatible with Lantus, which would allow the “holy grail” combination fast-acting/long acting insulin to be created. They are a top pick with an FDA review date of October 30th. Price estimate by that date of $7.00-$7.50. Once approved their insulin drug would revolutionize treatment of diabetes and will be targeting a massive market. Clinical tests and trials look good, overall very good outlook.

btibbz (< 20) Submitted: 4/19/2010 8:51:07 PM : Start Price: $4.66 BIOD Score: -93.26

FDA approval pending in October. Look for this to bounce off the 20 day MA at $4.41. Good long-term prognosis.

becon800 (99.81) Submitted: 1/22/2010 5:33:07 PM : Start Price: $5.24 BIOD Score: -109.21

Approval date in October should at least double the market value of this company. Clinical data looks great.

jwc1955 (< 20) Submitted: 1/9/2010 7:39:34 AM : Start Price: $4.86 BIOD Score: -99.15

came up with new drug for diabetics going for fda approval test have been good so far

biopharminvestor (< 20) Submitted: 9/16/2008 10:01:17 PM : Start Price: $5.49 BIOD Score: -100.03

Phase 3 data was not nearly as bad as Market thought. Drug delivery company + a produce that should file marketing application by 2008 EOY. Market Cap of $133 million is way undervalued. Also, don't sell Sol Steiner short. Also, very favorable insider and 'tute ownership

tenmiles (99.97) Submitted: 3/10/2008 11:25:48 AM : Start Price: $9.95 BIOD Score: -99.12

Insulin-related stocks are all being trashed in sympathy with Lily news to discontinue inhalable product. This company has its own challenges, including signficant insider selling, but at $10 likely represents a good entry point for risk-oriented types. Busted IPO with nearly 1/3 of market cap now in cash; good news on VIAject would likely send shares signicantly higher by year end.

ProtraderJC (< 20) Submitted: 1/15/2008 8:32:06 AM : Start Price: $23.25 BIOD Score: -95.21

This is an up and coming stock with great fundamentals and a great inside track. By the end of 2008, expect this stock to have more than doubled. Manufacturing and sales will commence and profits will turn green after a great IPO

zimn0016 (69.20) Submitted: 9/11/2007 12:23:48 AM : Start Price: $18.71 BIOD Score: +91.03

I am not impressed with their phase III insulin. Not exactly a novel therapy.

Doghair101 (21.98) Submitted: 8/13/2007 11:51:40 AM : Start Price: $16.05 BIOD Score: -90.20

Bio Diesel will be very profitable especially in areas that grow canola